VolitionRx publishes first peer-reviewed paper on Capture-Seq liquid biopsy technology

• VolitionRx published the first peer-reviewed paper detailing its Capture-Seq liquid biopsy approach for early cancer detection and minimal residual disease.
• Results were already presented in the paper, with early clinical findings indicating strong cancer detection with no false positives in two cohorts.
• The study suggests the method can isolate largely tumor-derived DNA from blood, potentially improving signal quality versus conventional liquid biopsy workflows.
• Commercial focus targets multi-cancer early detection and minimal residual disease, with an estimated combined annual total addressable market of about $36 billion.
• Technical evaluations are underway with potential licensing partners, signaling a push to accelerate commercialization via larger diagnostic companies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050817PR_NEWS_USPR_____LN19731) on August 05, 2026, and is solely responsible for the information contained therein.